Cannabis Use Disorder Clinical Trial
Official title:
Brain Imaging of Cannabinoid Receptors in Women
All participants will be healthy volunteers and all procedures will be completed for research purposes only. Two groups will be recruited, females who use cannabis (marijuana, MJ), and female who do not use cannabis (controls). Female MJ users will be enrolled in a protocol that includes an outpatient drug administration session and a 4-day/3-night inpatient stay on the Johns Hopkins Bayview Clinical Research Unit (CRU). During outpatient visits, MJ users will have an MRI, and complete MJ self-administration and cognitive performance sessions. MJ users will then reside on the CRU,and complete MJ abstinence, and self-report instruments for withdrawal discomfort. A positron emission tomography (PET) scan of brain cannabinoid type 1 receptors will also be completed. Non-users will complete MRI, PET imaging and cognitive testing under an outpatient protocol (no MJ administration).
The primary goals of this project are to examine whether use of cannabis alters brain cannabinoid type 1 receptor (CB1R) availability in females, and if severity of cannabis withdrawal is correlated with CB1 receptor availability. CB1R are widely distributed in the human brain and can be quantified using PET imaging with the radiotracer 11C-OMAR (Carbon-11-OMAR). The effects MJ use on brain CB1R have not been studied in females. The current study will enroll 10 female MJ users in an inpatient protocol that includes administration of smoked MJ, followed by monitored abstinence with daily behavioral assessments, and PET imaging with 11C-OMAR. PET data will collected in 10 matched controls for comparison. The proposed study is an important first step to determine whether localized CB1R changes in female MJ users help explain, and provide a neurobiological target for intervention. Results will increase knowledge of cannabinoid mechanisms of cannabis use and severity of dependence in females, an understudied population. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT04139668 -
Vivitrol Treatment for Cannabis Use Disorder
|
Phase 2 | |
Completed |
NCT01656707 -
Adaptive Treatment for Adolescent Cannabis Use Disorders
|
N/A | |
Completed |
NCT05005013 -
A Teleheath tDCS Approach to Decrease Cannabis Use
|
N/A | |
Recruiting |
NCT05292547 -
Repetitive Transcranial Magnetic Stimulation to People With Cannabis Use Disorder (SToP-C-rTMS x CUD)
|
N/A | |
Completed |
NCT02932215 -
Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder
|
Phase 1 | |
Completed |
NCT03430050 -
Progesterone for Cannabis Withdrawal
|
Early Phase 1 | |
Withdrawn |
NCT03629106 -
Effects of Cannabis Abstinence on Symptomology and Cognition in Bipolar Disorder
|
N/A | |
Completed |
NCT03334721 -
Gabapentin for Bipolar & Cannabis Use Disorders
|
Phase 2 | |
Recruiting |
NCT04721353 -
Reducing Cannabis Overuse With Prazosin
|
Phase 4 | |
Completed |
NCT03718520 -
The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
|
||
Completed |
NCT03624933 -
Effects of Cannabis Abstinence on Symptoms and Cognition in Depression
|
N/A | |
Recruiting |
NCT05836207 -
Rewards for Cannabis Abstinence-study
|
N/A | |
Not yet recruiting |
NCT06114212 -
Deep Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder
|
N/A | |
Recruiting |
NCT05855668 -
Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment
|
N/A | |
Recruiting |
NCT04517474 -
Comparing the Spanish Version of CANreduce With or Without Psychological Support and Treatment as Usual, Reducing Cannabis Use.
|
N/A | |
Recruiting |
NCT05885542 -
SCORE Emerging Adult Cannabis Use & Stress
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06085222 -
Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users
|
Phase 1 | |
Completed |
NCT03056482 -
Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)
|
Phase 4 | |
Not yet recruiting |
NCT06395389 -
A Brief Intervention for Cannabis Use
|
N/A |